RADIATION LOBECTOMY:
USING Y-90 TO PREPARE FOR LIVER SURGERY
How high-dose Y-90 delivered to the tumour-bearing liver lobe simultaneously controls cancer and induces contralateral liver hypertrophy โ converting patients with insufficient future liver remnant from 'unresectable' to safely operable.
analyticsAt a Glance
- check_circleRadiation lobectomy treats tumour AND grows the future liver remnant โ two clinical goals in one procedure
- check_circleHypertrophy of the contralateral lobe typically achieves 30โ40% FLR increase within 6โ9 months
- check_circleUnlike portal vein embolization (PVE), radiation lobectomy simultaneously treats the tumour during the waiting period
- check_circleCancerFax coordinates radiation lobectomy at specialist Y-90 and hepatobiliary surgery centres
What Is Radiation Lobectomy and Why Is It Used?
Major hepatic resection requires a sufficient future liver remnant (FLR) โ the volume of liver remaining after surgery must be large enough to sustain hepatic function and prevent post-hepatectomy liver failure (PHLF). When the FLR is too small (typically defined as <20โ25% of total liver volume for non-cirrhotic, <40% for cirrhotic), surgeons traditionally use portal vein embolization (PVE) to induce contralateral hypertrophy before operating. Radiation lobectomy offers an alternative that simultaneously treats the liver tumour while driving the same hypertrophic response.
โRadiation lobectomy is the only preparatory strategy for hepatic resection that treats the cancer at the same time as it grows the future liver remnant.โ
The Dual Purpose
High-dose Y-90 delivered to the tumour-bearing lobe achieves two simultaneous goals: tumour ablation/control (via radiation) and lobar atrophy (via the combined radiation and embolic injury to the treated lobe's vasculature). The contralateral lobe responds to the volume loss with compensatory hypertrophy.
Why This Matters โ The FLR Problem
Up to 20โ30% of potentially resectable HCC patients are ineligible for hepatectomy due to insufficient FLR โ often because cirrhosis has already reduced functional liver volume. Radiation lobectomy addresses this barrier by growing the FLR over 4โ9 months, during which tumour is simultaneously controlled.
The Radiation Lobectomy Process โ From Planning to Resection
Radiation lobectomy is a planned multi-step strategy, not a single procedure. The full pathway from initial volumetric assessment to surgery takes approximately 6โ12 months.
- 1
Liver Volumetric Assessment
CT or MRI liver volumetry is performed to measure total liver volume (TLV), tumour-bearing lobe volume, and FLR volume. The FLR ratio (FLR/TLV) determines whether the patient meets the threshold for safe major hepatectomy. If FLR < 20โ25% (non-cirrhotic) or < 40% (cirrhotic), a hypertrophy strategy is indicated.
- 2
MDT Discussion โ Radiation Lobectomy vs PVE
The hepatobiliary MDT discusses whether radiation lobectomy or portal vein embolization (PVE) is the appropriate hypertrophy strategy based on tumour location, lobar distribution, urgency of surgical timeline, and institutional expertise. Radiation lobectomy is preferred when simultaneous tumour treatment is desired during the hypertrophy phase.
- 3
Mapping Angiogram and MAA Scan
Mandatory pre-treatment workup โ hepatic arteriogram to map lobar anatomy and identify aberrant vessels, followed by Tc-99m MAA injection and SPECT/CT to quantify lung shunt fraction and confirm safety. Identical to any TARE planning session.
- 4
Radiation Lobectomy โ Y-90 Treatment Session
Y-90 microspheres are injected into the main right (or left) hepatic artery supplying the tumour-bearing lobe. Dose is calculated by partition model โ typically targeting โฅ120โ150 Gy to the treated lobe, often achieving >200 Gy at the tumour with deliberate segment/lobe atrophy expected.
- 5
Hypertrophy Monitoring โ CT/MRI Volumetry
Serial CT or MRI liver volumetry is performed at 4, 8, and 12 weeks post-radiation lobectomy to track FLR hypertrophy. Typical hypertrophy kinetics: 20โ30% FLR increase by 8 weeks, 30โ40% by 4โ6 months. The degree of FLR growth determines surgical timing.
- 6
Hepatic Resection โ When FLR Is Adequate
Once the FLR has grown to the safe resection threshold (typically 25โ30% for non-cirrhotic, >40% for cirrhotic), the hepatobiliary surgical team schedules major hepatectomy โ typically right hepatectomy. The atrophied, Y-90-treated lobe and the residual tumour within it are resected.
Radiation Lobectomy vs Portal Vein Embolization (PVE) โ Key Differences
PVE has been the standard FLR augmentation strategy for decades. Radiation lobectomy offers distinct advantages in oncological patients.
Radiation Lobectomy (Y-90)
- Simultaneous tumour treatmentY-90 radiation lobectomy treats the tumour during the waiting period โ eliminating the risk of tumour progression between the hypertrophy procedure and surgery.
- Combined tumour and portal responseBoth the radiation effect and the embolic component of Y-90 contribute to treated lobe atrophy โ potentially producing faster and more complete hypertrophy than PVE alone in some series.
- No risk of tumour seeding via portal circulationPVE can theoretically redistribute tumour cells through the portal circulation; radiation lobectomy does not involve the portal system.
- Higher oncological safety during wait timePatients waiting months for FLR hypertrophy after PVE remain at risk of tumour progression. Radiation lobectomy actively controls the tumour throughout this period.
Portal Vein Embolization (PVE)
- Simpler and more widely availablePVE requires only standard IR equipment โ no Y-90 supply chain, no nuclear medicine unit, no radiation dosimetry. Available at most hepatobiliary centres.
- Faster hypertrophy in selected patientsIn some series, PVE alone produces faster initial hypertrophy (first 4โ6 weeks) โ useful when surgical timing is more urgent.
- More established hypertrophy literaturePVE has decades of published volumetric data and a well-defined hypertrophy threshold literature โ radiation lobectomy hypertrophy kinetics are still being characterised.
- Does not preclude subsequent TACE if neededIf PVE fails to achieve adequate FLR growth, TACE to the tumour-bearing lobe can be added โ maintaining flexibility for the treating team.
Radiation Lobectomy โ Key Numbers
The quantitative benchmarks that define radiation lobectomy's role in the hepatic surgery preparation pathway.
- 30โ47%Median FLR hypertrophy achieved with radiation lobectomyPublished FLR volumetric increase across radiation lobectomy cohort studies โ comparable to or exceeding PVE-alone hypertrophy in most series.
- 4โ9 monthsTypical interval from radiation lobectomy to hepatic resectionLonger than PVE (4โ8 weeks), but this interval is oncologically beneficial โ continuous tumour control during the entire preparation period.
- ~80%Proportion of radiation lobectomy patients proceeding to planned resectionIn published series at expert centres, approximately 80% of radiation lobectomy patients achieve adequate FLR growth and proceed to surgical resection โ a high conversion rate for this challenging patient group.
More from the TARE / Y-90 Resource Library
Continue exploring Y-90 radioembolization โ from the clinical evidence in HCC to radiation segmentectomy and the complete workup guide.
Frequently Asked Questions: Radiation Lobectomy
How long after radiation lobectomy is surgery typically performed?
The interval between radiation lobectomy and hepatic resection is typically 4โ9 months โ longer than the 6โ8 weeks commonly used for PVE. This extended interval is necessary to allow adequate FLR hypertrophy, which follows a slower kinetic curve with radiation lobectomy than with PVE. Serial volumetric CT or MRI is performed every 4โ6 weeks, and surgery proceeds when the FLR/TLV ratio has reached the safe threshold (typically โฅ25โ30% for non-cirrhotic, โฅ40% for cirrhotic patients).
What if the FLR does not grow enough after radiation lobectomy?
In approximately 15โ20% of radiation lobectomy cases, FLR hypertrophy does not reach the safe surgical threshold. This may be due to: insufficient treated-lobe atrophy, underlying liver fibrosis limiting the regenerative response, or inadequate dose delivered to the treated lobe. In this situation, options include: additional TARE or TACE to the treated lobe, portal vein embolization added to the radiation lobectomy effect, ALPPS (associating liver partition with PVE for staged hepatectomy), or accepting that curative surgical resection is not achievable and continuing with locoregional or systemic therapy. The MDT team discusses all options at the post-radiation-lobectomy volumetric review.
Is radiation lobectomy available in China?
Yes. Radiation lobectomy is performed at specialist interventional oncology and hepatobiliary surgery centres in China โ including at institutions in Beijing, Shanghai, and Guangzhou with both Y-90 programmes and high-volume hepatic surgery. CancerFax identifies centres with coordinated IR + hepatobiliary surgery expertise for the full radiation lobectomy to resection pathway, and manages all coordination from initial volumetric assessment through to surgical admission.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Has Your HCC Been Called Unresectable Due to Insufficient Liver Remnant?
CancerFax reviews your liver volumetric data and tumour imaging to assess whether radiation lobectomy could make you surgically eligible โ and coordinates the full workup at specialist centres in China and India.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist and hepatobiliary surgeon before making treatment decisions.